期刊文献+

增殖诱导配体在大肠癌细胞株上的表达、定位及意义 被引量:1

The expression and cellular localization of APRIL in colorectal cancer cell lines
下载PDF
导出
摘要 目的了解增殖诱导配体(APRIL)在大肠癌细胞株上的表达、定位及意义。方法分别采用RT-PCR和Western Blotting技术检测APRIL在大肠癌细胞株SW620、LOVO、HCT116、HT29及SW480上的表达,同时采用ATP法检测这些大肠癌细胞株对5-FU的耐药性;以LOVO细胞为研究对象,用细胞免疫荧光技术分析APRIL蛋白的细胞定位情况。结果 RT-PCR和Western-blotting检测显示,APRIL在不同大肠癌细胞株中存在差异性表达,在LOVO、HCT116相对高表达,而在SW480、SW620、HT29相对低表达,其表达水平与5-FU耐药性呈正相关。激光共聚焦显微镜观察发现APRIL蛋白在LOVO细胞中主要定位于细胞浆,胞核中少见。结论 APRIL在大肠癌细胞株上有差异表达,其表达水平与大肠癌细胞株的5-FU耐药性有相关性。APRIL主要定位于胞浆。 Objective To investigate the cellular expression and localization of APRIL in colorectal cancer cell lines and their significance. Methods The cellular expression of APRIL mRNA and protein in five colorectal cancer cell lines LOVO, HCT116, SW480, SW620 and HT29, were determined by RT-PCR and Western Blotting, respectively, and their 5-FU resistance was measured by ATP method. The cellular localization of APRIL protein in colorectal cancer cell line LOVO was checked by fluorescence immunocytochemistry. Results Both the expression degree of APRIL mRNA and protein were different in five colorectal cancer cell lines. They were highly expressed in LOVO and HCT116, and lowly expressed in SW480, SW 620 and HT29, and their expression degrees were positively related to 5-FU resistance. It was showed by fluorescence immunocytochemistry technique that the APRIL protein in LOVO cell line was mainly located in cytoplasm, and little in nuclear. Conclusion The expression degree of APRIL was different in colorectal cancer cell lines, and positively related to 5-FU resistance. APRIL was mainly located in cytoplasm of colorectal cancer cell line.
出处 《现代消化及介入诊疗》 2011年第4期227-230,共4页 Modern Interventional Diagnosis and Treatment in Gastroenterology
基金 广东省自然科学基金(8151051501000040)
关键词 增殖诱导配体 大肠癌 表达 定位 耐药性 A proliferation-inducing ligand Colorectal cancer Expression Localization Drug resistance
  • 相关文献

参考文献10

  • 1Hahne M,Kataoka T,Schroter M,et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med, 1998,188:1185-1190.
  • 2SchwaUer J, Went P, Matthes T, et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin' s Disease. Leukemia, 2007,21:1324-1327.
  • 3Sun B, Wang H, Wang X, et al. A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer. Exp Lung Res, 2009, 35:486-500.
  • 4Dillon SR, Gross JA, Ansell SM, et al. An APRIL to remember: novel TNF ligands as therapeutic targets, Nat Rev Drug Discov, 2006,5:235-246.
  • 5Mhawech-Fauceqlia P, Allal A, Odunsi K, et al. Role of the tumour necrosis family ligand APRIL in solid turnout development: Retrospective studies in bladder, ovarian and head and neck carcinomas. Eur J Cancer, 2008,44:2097-2100.
  • 6Gabay C, Krenn V, Bosshard C, et al. Synovial tissues concentrate secreted APRIL. Arthritis Res Ther, 2009,11(5):R144.
  • 7Townsend M J, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev, 2010,237:264-283.
  • 8Dai S, Zheng Y, Chen B, et al. Two Gln187 mutants of human solu- ble APRIL inhibit proliferation of lung carcinoma A549 cells. Acta Biochim Pol, 2009,56:703-710.
  • 9Wang F, Chen L, Mao ZB, et al. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Pep, 2008,20:135-139.
  • 10Guadagnoli M, Kimberley FC, Phan U, et al. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood, 2011,117:6856-6865.

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部